Key result
Dabigatran offers predictable anticoagulation without routine monitoring for VTE prevention after hip and knee replacement.
Dabigatran etexilate is an oral direct thrombin inhibitor that provides predictable anticoagulation without monitoring, offering a convenient alternative to traditional anticoagulants for VTE prevention.
Answers are grounded in this paper and cite their sources.
Dabigatran offers a convenient monitoring-free option for post-orthopedic VTE prophylaxis; leaves open comparative effectiveness and long-term safety versus other agents.
Thrombin is a key enzyme in the blood coagulation cascade and a major factor in the initiation and propagation of thrombosis. Thrombin inhibition therefore represents a therapeutic target for numerous thromboembolism-related disorders, such as venous thromboembolism (VTE) and arterial thrombosis [1]. Historically, antithrombotic therapy was mainly based on the orally-administered vitamin K antagonists (VKAs; e.g., warfarin), or on parenteral indirect thrombin inhibitors such as unfractionated heparin and low-molecular weight heparins via activation of antithrombin. Despite high clinical effectiveness, these anticoagulants have important limitations. VKAs have a slow onset/offset of action, and a narrow therapeutic range requiring frequent anticoagulation monitoring and dosage adjustment, while heparins have only a parenteral formulation [2]. These disadvantages provide the impetus for the development of newer anticoagulants, the direct thrombin inhibitors (DTIs) and oral factor Xa inhibitors. The DTIs inactivate thrombin directly by blocking its catalytic or fibrinogen-binding sites, or both [1]. Independence from co-factor levels (e.g., antithrombin III) makes their action more predictable, and their ability to inhibit both plasma and fibrin-bound thrombin predisposes to high anticoagulant activity [3]. The first member of the group, ximelagatran, revealed a number of attractive advantages over traditional VKAs, such as low interindividual variability, rapid onset of action and a predictable anti coagulant response, eliminating the requirement for routine anticoagulation monitoring [4]. Several large clinical trials on over 30,000 patients demonstrated that ximelagatran had an efficacy and risk of bleeding similar to the traditional anticoagulants [5]. However, ximelagatran was found to be associated with risks of hepatotoxicity [6], as well as a higher number of cardiovascular events after cessation of treatment, raising the possibility of a ximelagatran-induced rebound effect on the coagulation system [7]. As a result, ximelagatran was withdrawn from the market. The next member of the oral DTI family, dabigatran etexilate, is a synthetic small benzamidine-based molecule that binds reversibly to the active site of the thrombin, thus inhibiting it [8]. Dabigatran benefits from its oral formulation and, in contrast to warfarin, dabigatran can be administered as a fixed dose with a rapid onset of action. Dabigatran provides a predictable and consistent anticoagulation effect without the need for coagulation monitoring. As it does not undergo hepatic metabolism, dabigatran has a relatively low potential for drug–drug interaction without significant drug–food interactions. In comparison with enoxaparin, dabigatran etexilate has a similar level of safety and efficacy, but its primary benefit is its convenience due to oral administration [9]. Therefore, dabigatran etexilate promises to not only decrease demands on hospital time and resources, but also provides us with an orally administered anti coagulant that can be prescribed safely on an out-patient basis. The risk of liver damage as a side effect of dabigatran etexilate has been extensively investigated, but not observed until now. However, short-term exposure to ximelagatran also did not appear to increase the risk of liver toxicity, whereas its long-term administration led to a few cases of fatal hepatotoxicity. Therefore, further observations of long-term dabigatran safety are required. Dabigatran etexilate has, however, been approved in the EU for the primary prevention of VTE in patients with elective total hipand knee-replacement surgery, and this decision was based on the evidence available from the different clinical studies on dabigatran [101].
No takes yet. Share an insight, caveat, or question.
Shantsila et al. (2008) conducted a review in Thromboembolism-related disorders. Dabigatran etexilate vs. Traditional anticoagulants was evaluated. Dabigatran etexilate is an oral direct thrombin inhibitor offering predictable anticoagulation without routine monitoring, approved in the EU for VTE prevention following hip and knee replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: